BMS-986176, also known as LX9211, is a highly selective, CNS penetrant, potent AAK1 inhibitor from a novel class of bi(hetero)aryl ethers. BMS-986176/LX9211 (34) showed excellent efficacy in two rodent neuropathic pain models and excellent central nervous system (CNS) penetration and target engagement at the spinal cord with an average brain to plasma ratio of 20 in rat. The compound exhibited favorable physicochemical and pharmacokinetic properties, had an acceptable preclinical toxicity profile, and was chosen for clinical trials.
仅供研究使用。 我们不向患者出售。
名称 | BMS-986176 |
---|---|
Iupac 化学名称 | ( S)-1-((2',6-Bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin |
同义词 | LX9211; LX-9211; LX 9211; BMS-986176; BMS 986176; BMS986176; AAK1-IN-1; |
英文同义词 | LX9211; LX-9211; LX 9211; BMS-986176; BMS 986176; BMS986176; AAK1-IN-1; |
分子式 | C19H23F4N3O |
分子量 | 385.40 |
Smile | CC(C)C[C@@](N)(C)COC1=C(C(F)F)N=C(C2=CC(C(F)F)=NC=C2)C=C1 |
InChiKey | RKAHOQATMSONTM-IBGZPJMESA-N |
InChi | InChI=1S/C19H23F4N3O/c1-11(2)9-19(3,24)10-27-15-5-4-13(26-16(15)18(22)23)12-6-7-25-14(8-12)17(20)21/h4-8,11,17-18H,9-10,24H2,1-3H3/t19-/m0/s1 |
Cas号 | 1815613-42-3 |
相关CAS号 |
包装 | 价格 | 库存 | 纯度 | 备货期 |
---|---|---|---|---|
大货 | 询价 | 询价 | 询价 |
外观性状 | Solid powder |
---|---|
纯度 | 98% Min. |
存储 | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
可溶性 | Soluble in DMSO |
处理方式 | |
运输条件 | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
海关编码 |
Targets | |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |
1: Luo G, Chen L, Kostich WA, Hamman B, Allen J, Easton A, Bourin C, Gulianello M, Lippy J, Nara S, Maishal TK, Thiyagarajan K, Jalagam P, Pattipati SN, Dandapani K, Dokania M, Vattikundala P, Sharma V, Elavazhagan S, Verma MK, Das ML, Wagh S, Balakrishnan A, Johnson BM, Santone KS, Thalody G, Denton R, Saminathan H, Holenarsipur VK, Kumar A, Rao A, Putlur SP, Sarvasiddhi SK, Shankar G, Louis JV, Ramarao M, Conway CM, Li YW, Pieschl R, Tian Y, Hong Y, Ditta J, Mathur A, Li J, Smith D, Pawluczyk J, Sun D, Yip S, Wu DR, Vetrichelvan M, Gupta A, Wilson A, Gopinathan S, Wason S, Bristow L, Albright CF, Bronson JJ, Macor JE, Dzierba CD. Discovery of (S)-1-((2',6-Bis(difluoromethyl)-[2,4' -bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine (BMS-986176/LX-9211): A Highly Selective, CNS Penetrable, and Orally Active Adaptor Protein-2 Associated Kinase 1 Inhibitor in Clinical Trials for the Treatment of Neuropathic Pain. J Med Chem. 2022 Mar 8. doi: 10.1021/acs.jmedchem.1c02131. Epub ahead of print. PMID: 35257579.
2: Bundrant L, Hunt TL, Banks P, Gopinathan S, Boehm KA, Kassler-Taub K, Tyle P, Wilson A, Warner C, Wason S. Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants. Clin Ther. 2021 Jun;43(6):1029-1050. doi: 10.1016/j.clinthera.2021.04.014. Epub 2021 Jun 6. PMID: 34108079.